Toshiba America Medical Systems Names Satrajit Misra Vice President Of Marketing

TUSTIN, Calif.--(BUSINESS WIRE)--Toshiba America Medical Systems, Inc. announced that Satrajit Misra has been named vice president, Marketing. Misra will be responsible for overseeing all business units, Corporate and Strategic Communications, Clinical Collaborations and Healthcare Economics with the goals of continuing Toshiba's growth and maintaining its commitment to putting customers first.

"Committed to People, Committed to the Future"

"Satrajit Misra has consistently demonstrated his leadership skills by driving year-over-year growth for our CT business," said Shuzo Yamamoto, president and CEO, Toshiba America Medical Systems. "He brings to Toshiba expertise in several different modalities as well as successful experience in marketing, sales and system development. Mr. Misra has also developed synergetic relationships with colleagues around the world and we are looking forward to his application of this robust skill set to his new role."

Misra was most recently the senior director, CT Business Unit at Toshiba, increasing sales and launching new products, like the award-winning AquilionTM ONE ViSION. Prior to joining Toshiba, Misra served as senior director and head of product marketing for Nuclear Medicine at Philips Healthcare and was a medical systems director of Business Management at Siemens. He has a bachelor of science and a bachelor of technology in applied physics from the University of Calcutta in India and attended the School of Business and Economic Studies at the University of Leeds in the United Kingdom.

About Toshiba America Medical Systems, Inc.

With headquarters in Tustin, Calif., Toshiba America Medical Systems markets, sells, distributes and services radiology and cardiovascular systems, including CT, MR, ultrasound, X-ray and cardiovascular equipment, and coordinates clinical diagnostic imaging research for all modalities in the United States. For more information, visit Toshiba's website at www.medical.toshiba.com.

About Toshiba Medical Systems Corporation

Toshiba Medical Systems Corporation is a leading worldwide provider of medical diagnostic imaging systems and comprehensive medical solutions, such as CT, X-ray and vascular, ultrasound, nuclear medicine and MRI systems, as well as information systems for medical institutions. Toshiba Medical Systems Corporation has been providing medical products for over 80 years. Toshiba Medical Systems Corporation is a wholly owned subsidiary of Toshiba. Visit Toshiba Medical Systems Corporation's website at www.toshibamedicalsystems.com.

About Toshiba

Toshiba Corporation, a Fortune 500 company, channels world-class capabilities in advanced electronic and electrical products and systems into five strategic business domains: Energy & Infrastructure, Community Solutions, Healthcare Systems & Services, Electronic Devices & Components, and Lifestyles Products & Services. Guided by the principles of The Basic Commitment of the Toshiba Group, "Committed to People, Committed to the Future," Toshiba promotes global operations towards securing "Growth Through Creativity and Innovation" and is contributing to the achievement of a world in which people everywhere live in a safe, secure and comfortable society.

Founded in Tokyo in 1875, today's Toshiba is at the heart of a global network of over 590 consolidated companies employing over 200,000 people worldwide, with annual sales surpassing 6.5 trillion yen (US $63 billion). To find out more about Toshiba, visit www.toshiba.co.jp/index.htm.

Contacts

Toshiba America Medical Systems, Inc.
Rachel Miller, 714-669-7623
[email protected]
or
Michael Stewart, 310-437-2523
[email protected]

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.